Free Trial

Marker Therapeutics (MRKR) Competitors

Marker Therapeutics logo
$0.93 +0.03 (+3.30%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$0.91 -0.01 (-1.48%)
As of 08/29/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MRKR vs. COEP, KALA, MNOV, GNTA, INMB, CUE, IMMX, SLGL, ALGS, and ALXO

Should you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Coeptis Therapeutics (COEP), KALA BIO (KALA), MediciNova (MNOV), Genenta Science (GNTA), INmune Bio (INMB), Cue Biopharma (CUE), Immix Biopharma (IMMX), Sol-Gel Technologies (SLGL), Aligos Therapeutics (ALGS), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry.

Marker Therapeutics vs. Its Competitors

Coeptis Therapeutics (NASDAQ:COEP) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

In the previous week, Marker Therapeutics had 6 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 7 mentions for Marker Therapeutics and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.50 beat Marker Therapeutics' score of 0.06 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Coeptis Therapeutics Positive
Marker Therapeutics Neutral

Coeptis Therapeutics has a beta of -0.59, suggesting that its share price is 159% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.

Marker Therapeutics has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coeptis Therapeutics$263.56K243.60-$10.88M-$5.80-2.30
Marker Therapeutics$6.59M1.82-$10.73M-$1.37-0.68

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 7.8% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Coeptis Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -271.12%. Marker Therapeutics' return on equity of -114.59% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coeptis TherapeuticsN/A -201.73% -108.46%
Marker Therapeutics -271.12%-114.59%-90.31%

Marker Therapeutics has a consensus target price of $13.17, indicating a potential upside of 1,322.35%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coeptis Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Marker Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50

Summary

Marker Therapeutics beats Coeptis Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRKR vs. The Competition

MetricMarker TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.60M$2.49B$5.66B$9.84B
Dividend YieldN/A1.67%3.93%4.04%
P/E Ratio-0.6822.8083.2726.61
Price / Sales1.82509.21451.26176.28
Price / CashN/A177.7737.7059.65
Price / Book1.145.9810.556.59
Net Income-$10.73M$32.94M$3.27B$266.12M
7 Day Performance-28.24%-1.28%0.42%0.17%
1 Month Performance-32.92%3.54%5.91%3.02%
1 Year Performance-73.32%-3.68%48.11%19.69%

Marker Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRKR
Marker Therapeutics
3.4024 of 5 stars
$0.93
+3.3%
$13.17
+1,322.3%
-73.6%$11.60M$6.59M-0.6860Gap Up
COEP
Coeptis Therapeutics
0.5463 of 5 stars
$13.65
+1.4%
N/A+233.5%$64.88MN/A-2.352News Coverage
Positive News
Gap Up
KALA
KALA BIO
3.4747 of 5 stars
$8.78
-4.7%
$13.00
+48.1%
+90.5%$64.66M$3.89M-1.2930Positive News
MNOV
MediciNova
2.1941 of 5 stars
$1.32
+0.6%
$7.00
+430.3%
+0.0%$64.37M$1M-5.2810Analyst Forecast
Gap Up
GNTA
Genenta Science
2.3286 of 5 stars
$3.50
-0.4%
$25.00
+615.3%
-2.8%$64.20MN/A0.007News Coverage
Gap Up
High Trading Volume
INMB
INmune Bio
1.9459 of 5 stars
$2.24
-7.1%
$18.40
+721.4%
-70.4%$64.07M$10K-0.9010
CUE
Cue Biopharma
2.4929 of 5 stars
$0.82
-0.9%
N/A+8.2%$63.47M$9.29M-1.4660High Trading Volume
IMMX
Immix Biopharma
3.2768 of 5 stars
$2.10
-4.1%
$7.00
+233.3%
+4.7%$63.15MN/A-2.739News Coverage
Analyst Downgrade
SLGL
Sol-Gel Technologies
0.7037 of 5 stars
$21.00
-7.4%
N/A+247.9%$63.15M$11.54M-17.0750Gap Down
ALGS
Aligos Therapeutics
4.3523 of 5 stars
$10.21
+0.1%
$50.00
+389.7%
-19.8%$62.74M$3.94M-0.5290Positive News
High Trading Volume
ALXO
ALX Oncology
3.1182 of 5 stars
$1.10
-6.0%
$3.30
+200.0%
-49.1%$62.65MN/A-0.5040News Coverage

Related Companies and Tools


This page (NASDAQ:MRKR) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners